Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Didanosine.

M J Shelton1, A M O'Donnell, G D Morse

  • 1Center for Clinical Pharmacy Research, State University of New York, Buffalo.

The Annals of Pharmacotherapy
|May 1, 1992
PubMed
Summary
This summary is machine-generated.

Didanosine (ddI) shows preliminary efficacy in treating advanced HIV infection, improving CD4+ counts and p24 antigen levels. Further studies are needed to confirm survival benefits and compare didanosine with zidovudine (ZDV).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The implications of vaping for the anaesthetist.

BJA education·2021
Same author

Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Clinical pharmacology and therapeutics·2013
Same author

Investigation of L-type Ca(2+) current in the aganglionic bowel segment in Hirschsprung's disease.

Neurogastroenterology and motility·2012
Same author

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.

HIV medicine·2011
Same author

Survey of the fatty acid composition of retail milk differing in label claims based on production management practices.

Journal of dairy science·2010
Same author

Hot topic: Enhancing omega-3 fatty acids in milk fat of dairy cows by using stearidonic acid-enriched soybean oil from genetically modified soybeans.

Journal of dairy science·2010
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Clinical Medicine

Background:

  • Didanosine (2',3'-dideoxyinosine [ddI]) is an antiretroviral drug used in HIV treatment.
  • It is an alternative for patients intolerant to zidovudine (ZDV) or experiencing disease progression on ZDV.

Purpose of the Study:

  • To review the chemistry, intracellular metabolism, pharmacokinetics, and clinical experience with didanosine (ddI).

Main Methods:

  • Systematic review of English-language articles and conference proceedings.
  • Inclusion of Phase I studies and significant abstracts evaluating didanosine.
  • Data extraction focused on HIV surrogate markers (CD4+ lymphocytes, p24 antigen).

Main Results:

  • Didanosine demonstrates a long intracellular half-life and low bone-marrow toxicity compared to ZDV.

Related Experiment Videos

  • In vitro activity against ZDV-resistant HIV strains.
  • Phase I studies show beneficial effects on CD4+ counts and p24 antigen; however, peripheral neuropathy and pancreatitis are dose-limiting toxicities.

    • Conclusions:

    • Didanosine shows preliminary efficacy in late-stage HIV infection.
    • Its impact on patient survival and comparative efficacy against ZDV require further investigation.
    • The utility of didanosine in combination therapy remains under evaluation.